RCUS
Price:
$15.72
Market Cap:
$1.44B
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic can...[Read more]
Industry
Biotechnology
IPO Date
2018-03-15
Stock Exchange
NYSE
Ticker
RCUS
According to Arcus Biosciences, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -5.05. This represents a change of -82.04% compared to the average of -28.11 of the last 4 quarters.
The mean historical PE Ratio of Arcus Biosciences, Inc. over the last ten years is -2.45. The current -5.05 PE Ratio has changed 20.49% with respect to the historical average. Over the past ten years (40 quarters), RCUS's PE Ratio was at its highest in in the September 2020 quarter at 147.22. The PE Ratio was at its lowest in in the March 2024 quarter at -99.56.
Average
-2.45
Median
-6.67
Minimum
-23.23
Maximum
52.95
Discovering the peaks and valleys of Arcus Biosciences, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 109.10%
Maximum Annual PE Ratio = 52.95
Minimum Annual Increase = -534.39%
Minimum Annual PE Ratio = -23.23
Year | PE Ratio | Change |
---|---|---|
2023 | -4.60 | -17.44% |
2022 | -5.58 | -110.53% |
2021 | 52.95 | -534.39% |
2020 | -12.19 | 109.10% |
2019 | -5.83 | -22.46% |
2018 | -7.52 | -44.83% |
2017 | -13.63 | -41.34% |
The current PE Ratio of Arcus Biosciences, Inc. (RCUS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
14.26
5-year avg
4.95
10-year avg
-2.45
Arcus Biosciences, Inc.’s PE Ratio is greater than Cullinan Oncology, Inc. (-6.96), greater than Annexon, Inc. (-6.50), greater than Structure Therapeutics Inc. (-18.15), less than Relay Therapeutics, Inc. (-2.57), greater than Day One Biopharmaceuticals, Inc. (-7.39), less than Acumen Pharmaceuticals, Inc. (-2.06), less than X4 Pharmaceuticals, Inc. (7.41), less than Inozyme Pharma, Inc. (-3.48), greater than VectivBio Holding AG (-7.94), less than PTC Therapeutics, Inc. (-5.05), greater than Blueprint Medicines Corporation (-26.44), less than Krystal Biotech, Inc. (49.72), greater than Intercept Pharmaceuticals, Inc. (-13.55), greater than Madrigal Pharmaceuticals, Inc. (-10.23), less than Immix Biopharma, Inc. (-2.98), less than CNS Pharmaceuticals, Inc. (-0.00), less than Hepion Pharmaceuticals, Inc. (-0.15), less than Freeline Therapeutics Holdings plc (-0.57), less than AVROBIO, Inc. (2.07), greater than Icosavax, Inc. (-8.27), greater than Apellis Pharmaceuticals, Inc. (-15.28), greater than iTeos Therapeutics, Inc. (-5.43), greater than TScan Therapeutics, Inc. (-6.03),
Company | PE Ratio | Market cap |
---|---|---|
-6.96 | $1.04B | |
-6.50 | $607.51M | |
-18.15 | $2.11B | |
-2.57 | $835.47M | |
-7.39 | $1.25B | |
-2.06 | $133.38M | |
7.41 | $109.78M | |
-3.48 | $312.42M | |
-7.94 | $1.06B | |
-5.05 | $2.43B | |
-26.44 | $5.47B | |
49.72 | $5.29B | |
-13.55 | $794.69M | |
-10.23 | $5.30B | |
-2.98 | $54.08M | |
-0.00 | $4.60M | |
-0.15 | $4.20M | |
-0.57 | $28.28M | |
2.07 | $5.24M | |
-8.27 | $769.04M | |
-15.28 | $5.00B | |
-5.43 | $540.52M | |
-6.03 | $294.00M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arcus Biosciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Arcus Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Arcus Biosciences, Inc.'s PE Ratio?
How is the PE Ratio calculated for Arcus Biosciences, Inc. (RCUS)?
What is the highest PE Ratio for Arcus Biosciences, Inc. (RCUS)?
What is the 3-year average PE Ratio for Arcus Biosciences, Inc. (RCUS)?
What is the 5-year average PE Ratio for Arcus Biosciences, Inc. (RCUS)?
How does the current PE Ratio for Arcus Biosciences, Inc. (RCUS) compare to its historical average?